Angiopoietin-like 3-derivative LNA043 for cartilage regeneration in osteoarthritis: a randomized phase 1 trial

Nicole Gerwin(Novartis (Switzerland)), Michaela Kneissel(Novartis (Switzerland)), Jörg Goldhahn(Schulthess-Klinik), Abdelkader Seroutou(Novartis (Switzerland)), Thomas Peters(Novartis (Switzerland)), Sandra Walter(Novartis (Switzerland)), Sophie Brachat(Novartis (Switzerland)), Keith A. Wharton(CS Diagnostics), Nelly Laplanche(Novartis (Switzerland)), Jimmy Elliott(Genomics Institute of the Novartis Research Foundation), Sabine Guth(Novartis (Switzerland)), Kristen Johnson(Scripps Research Institute), Celeste Scotti(Novartis (Switzerland)), Florine Polus(Novartis (Switzerland)), Jian Shi(National Center for Nanoscience and Technology), Didier Laurent(Novartis (Switzerland)), Ronenn Roubenoff(Novartis (Switzerland)), Magali Belaud(Novartis (Switzerland)), Gustavo Glowacki(Novartis (Switzerland)), Igor Voštiar(Novartis (Switzerland)), Mara Fornaro(Novartis (Switzerland)), Joseph Gimbel(Arizona Research Center), Matthias Schieker(Ludwig-Maximilians-Universität München), Christine Halleux(World Health Organization), Yufei Li(Huazhong Agricultural University), Yunyu Zhang(Novartis (United States)), Jochen Paul(Gesundheitsamt), Carsten Jacobi(Novartis (Switzerland)), Ina Krämer, Subhajit Choudhury(IQVIA (India))
Nature Medicine
December 1, 2022
Cited by 63


Related Papers